Impact of Dual Antiplatelet Therapy Duration on Stent Thrombosis Risk in Patients Undergoing Complex Percutaneous Coronary Intervention: A Meta-Analysis - Summary - MDSpire
Advertisement
Impact of Dual Antiplatelet Therapy Duration on Stent Thrombosis Risk in Patients Undergoing Complex Percutaneous Coronary Intervention: A Meta-Analysis
To assess whether the duration of dual antiplatelet therapy (DAPT) impacts the risk of ischemic events, particularly stent thrombosis (ST), myocardial infarction (MI), and all-cause mortality in patients undergoing complex percutaneous coronary intervention (PCI).
Key Findings:
Extended DAPT may reduce the risk of stent thrombosis in complex PCI patients, suggesting a need for tailored DAPT strategies.
Current guidelines suggest varying DAPT durations based on ischemic and hemorrhagic risk, highlighting the importance of individualized patient care.
Variations in DAPT duration are common in clinical practice due to patient and physician factors, necessitating further investigation into optimal strategies.
Interpretation:
The findings suggest that longer DAPT duration could be beneficial in reducing ST risk, but the balance between ischemic and bleeding risks must be carefully managed, with consideration for individual patient profiles.
Limitations:
Variability in definitions of complex PCI and DAPT regimens across studies may affect the generalizability of results.
Potential publication bias and heterogeneity among included studies could influence the overall conclusions drawn from the meta-analysis.
Conclusion:
Further research is needed to establish definitive recommendations for DAPT duration in complex PCI patients, particularly focusing on the balance of ischemic and bleeding risks and exploring the impact of patient-specific factors.
by Fiorenzo Simonetti, Claudia Carassia, Hector Alfonso Alvarez Covarrubias, Michael Joner, Thorsten Kessler, Tobias Rheude, Hendrik Sager, Felix Voll, Moritz von Scheidt, Erion Xhepa, Adnan Kastrati, Salvatore Cassese
